AdPEDF gene therapy

Drug Profile

AdPEDF gene therapy

Alternative Names: Ad35 adenovector delivery; Ad35PEDF; AdGVPEDF.11D; AdPEDF; AdPEDF.11D; Blindness prevention programme - GenVac; PEDF gene therapy; Pigment epithelium-derived factor gene therapy - GenVec

Latest Information Update: 29 Jun 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator National Institutes of Health (USA); Northwestern University
  • Developer GenVec
  • Class Eye disorder therapies; Gene therapies
  • Mechanism of Action Angiogenesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Age-related macular degeneration; Diabetic retinopathy

Most Recent Events

  • 16 Jun 2017 GenVec was acquired by Intrexon Corporation
  • 21 May 2008 GenVec receives grant from National Eye Institute for AdPEDF gene therapy development in wet AMD
  • 29 Feb 2008 Phase I evaluation is ongoing for Age-related macular degeneration
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top